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Abstract
Macrophages promote tissue remodeling but few mechanisms exist to modulate their activity during tissue fibrosis. Serum
amyloid P (SAP), a member of the pentraxin family of proteins, signals through Fcc receptors which are known to affect
macrophage activation. We determined that IPF/UIP patients have increased protein levels of several alternatively activated
pro-fibrotic (M2) macrophage-associated proteins in the lung and monocytes from these patients show skewing towards an
M2 macrophage phenotype. SAP therapeutically inhibits established bleomycin-induced pulmonary fibrosis, when
administered systemically or locally to the lungs. The reduction in aberrant collagen deposition was associated with a
reduction in M2 macrophages in the lung and increased IP10/CXCL10. These data highlight the role of macrophages in
fibrotic lung disease, and demonstrate a therapeutic action of SAP on macrophages which may extend to many fibrotic
indications caused by over-exuberant pro-fibrotic macrophage responses.
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Introduction
The substantial morbidity and mortality associated with
pulmonary fibrosis makes this heterogeneous group of diseases
an important area of research. This group of disorders
encompasses the interstitial lung diseases (ILD), idiopathic
pulmonary fibrosis (IPF/UIP), radiation-induced pulmonary
fibrosis, scleroderma-induced lung disease (SSc-ILD), and drug-
induced lung toxicity. Collectively these pathologies are associated
with uncontrolled matrix deposition, collagen production, apo-
ptosis, and alveolar destruction. Airway based diseases can also
develop fibrosis and lead to chronic airway obstruction and
persistent gas exchange abnormalities. Despite its clinical impor-
tance, an underlying common mechanism contributing to fibrosis
remains obscure.
A monocyte-derived cell type associated with the maintenance
and progression of ILD, notably IPF/UIP, is the alternatively
activated (M2) macrophage. This phenotype of macrophage is the
predominant macrophage found in the lungs of IPF/UIP patients
[1]. These cells express IL13Ra2 and signaling though this high
affinity IL13 receptor results in TGFb1 expression, thus promoting
the fibrotic milieu [2]. Further, M2 macrophages also express
higher levels of scavenging receptors CD163, mannose receptor
(MRC-1, CD206) and macrophage scavenging receptor (MSR-1)
as they differentiate from monocytes [3,4].
M2 macrophages are capable of synthesizing pro-fibrotic
mediators, but this cell type is inefficient at supporting the host
defense provided by the classical M1 macrophage [3]. This
alteration in macrophage phenotype in IPF/UIP patients may
explain why these patients succumb to repeated bouts of
pulmonary infections or exacerbation of disease, which has been
correlated with a more rapid decline in lung function and
ultimately death [5]. Therefore, regulating the phenotype of this
cell is an attractive therapeutic strategy for lung fibrosis, as this cell
type produces high levels of pro-fibrotic cytokines and growth
factors in vitro, which may contribute towards the continuation of
the fibrotic milieu.
Serum amyloid P (SAP), a member of the pentraxin family of
proteins has been shown to inhibit fibrosis in a number of organ
sites during preclinical animal models, which in part is due to an
inhibition of the differentiation of peripheral blood mononuclear
cells into CD45
+/collagen I
+ cells called fibrocytes [6,7,8]. SAP
binds to Fcc receptors [9] and the anti-fibrotic activities of SAP
have been shown to be mediated through Fcc receptors [10]
which affect peripheral blood monocyte differentiation and
activation states.
We initially phenotyped monocytes from IPF/UIP patients and
detected increased CD163 expression, which correlated with
increased M2 associated proteins in the circulation and lung. We
next hypothesized that the anti-fibrotic therapeutic benefit
PLoS ONE | www.plosone.org 1 March 2010 | Volume 5 | Issue 3 | e9683mediated by SAP during bleomycin-induced lung fibrosis is via
directing monocyte/M2 macrophage activation.
Results
Enhanced alternative macrophage phenotype in IPF/UIP
patient lung and circulation
To determine the potential for altered monocyte/macrophage
phenotype in IPF/UIP, we initially assessed the levels of various
mediators in the circulation of patients with stable and progressive
IPF/UIP. 25 subjects were recruited. Of these, thirteen had IPF/
UIP and twelve were control subjects. There was no difference in
the control and IPF/UIP subjects in terms of sex, race, age, and
comorbid conditions including obesity, coronary disease, or renal
disease. While no control subjects smoked, seven IPF/UIP subjects
had a significant smoking history (p,0.0005, Table 1). IPF/UIP
patients were then stratified into ‘‘Progressive’’ or ‘‘Stable’’ based
on their clinical outcome at one year. Seven patients qualified as
‘‘progressive’’ and six qualified as ‘‘stable.’’ This included:
Significant (10%) decline in FVC in the 12 months following
enrollment, new oxygen requirement, hospitalization or treatment
for exacerbation of IPF/UIP, and death by any cause. Using these
criteria, seven IPF/UIP patients qualified as ‘‘progressive’’ and six
were ‘‘stable.’’ There was no difference in the baseline character-
istics of groups including race, sex, age, comorbid conditions,
biopsy proven diagnosis, and lung function. These data are shown
in Table 2.
We analyzed plasma from IPF/UIP and control subjects and
focused on the two monocyte-associated markers IL1RA and
MCP1/CCL2 (Fig. 1). Here we determined that patients with
IPF/UIP had significantly increased plasma IL1RA (Fig. 1 A) and
MCP1/CCL2 (Fig. 1 B) in comparison to healthy age-matched
control patients. When stratifies into stable versus progressive,
IPF/UIP patients with stable disease only trended towards an
increase in IL1RA compared to controls, however there was no
increase in MCP1/CCL2 in the circulation of IPF/UIP patients
with stable disease. Interestingly, IPF/UIP patients with progres-
sive disease had significantly greater levels of MCP1/CCL2
compared to stable disease patients (Fig. 1 B). Flow cytometric
analysis indicated that a greater percentage of isolated CD14+
monocytes also expressed CD163 in IPF/UIP patients in
comparison to healthy age-matched controls (Fig. 1 C). In
addition, CD163+ monocytes were increased in patients with
progressive versus stable disease.
Previous reports have demonstrated that M2 macrophages are
present in the lungs of IPF/UIP patients [1,11]. Using Luminex
TM
technology we measured the levels of specific macrophage-
associated mediators at the protein level in lysates of whole lung
tissue obtained from biopsy samples from IPF/UIP patients taken
at time of diagnosis and compared it to control lung tissue from the
normal margins of lung tumor resections. For this study we
measured markers associated with M1/M2 macrophages, namely
IP10/CXCL10, MIP1a/CCL3 and fractalkine/CX3CL1 for M1
and IL4, IL13, IL1RA and resistin for M2 macrophage
phenotype. We observed significantly elevated levels of IL13 and
IL1RA in IPF/UIP lung tissue (Fig. 2 A,B). We also detected a
trend towards an increase in resistin levels in the lung of IPF/UIP
patients compared to non-IPF/UIP, although the levels were not
significantly different (Fig. 2 C). In contrast, the lungs of IPF/UIP
patients had significantly decreased levels of the M1 macrophage-
associated protein fractalkine/CX3CL1 (Fig. 2 D). There was no
difference in IP10/CXCL10, MIP1a/CCL3 or IL4 levels in IPF
compared to non-fibrotic tissue (data not shown).
Attenuated alternative macrophage activation mediated
by SAP in established bleomycin-induced lung fibrosis
Our previous data show that macrophages in the lung are
largely of an M2 phenotype by day 11 after bleomycin [12]. A
previous study in has demonstrated that murine serum-derived
SAP reduces fibrosis in a mouse intratracheal bleomycin model
[7]. Here, as expected, human SAP also significantly reduced the
histopathological extent of bleomycin-induced collagen deposition
(Fig. 3 A) and the generation of collagen at the protein (Fig. 3 B)
and gene level (Fig. 3 C).
To extend the initial published findings, we next evaluated the
phenotype of macrophages in bleomycin model, we initially
stained lung sections for IL13Ra2 expression. In the lung,
IL13Ra2 is highly expressed on both the epithelium and on M2
macrophages [13]. We stained lung sections with anti-IL13Ra2
and found comparable levels of epithelial IL13Ra2 expression
between vehicle and SAP-treated bleomycin challenged mice at
day 21 (Fig. 3 D). However, there was a reduction in the number
of IL13Ra2+ alveolar macrophages in the lungs of SAP treated
mice in comparison to vehicle control treated mice (Fig. 3 D).
Table 1. IPF vs control.
Category IPF n=13 Control n=12 Composite P Value per Category
Sex Female 2 (15.4) 4 (33.3%) 0.38
Male 11 (84.63%) 8 (66.7%)
Smoking History Ever 5 (38.5%) 0 0.002
Never 8 (61.5%) 0
Race Nonwhite 4 (30.7%) 2 (8.3%) 0.64
White 9 (61.3%) 10 (91.7%)
Obese Nonobese 10 (76.9%) 10 (83.3%) 1.0
Obese 3 (23.1%) 2 (16.7%)
Age Years 66.5610.9 59.25616.0 0.19
Coronary disease Incidence 1 (7.6%) 1 (8.3%) 1.0
Kidney disease Incidence 0 0 NS
Continuous variables are expressed as mean 6 standard deviation.
doi:10.1371/journal.pone.0009683.t001
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DNA technology in the lungs of bleomycin challenged mice
treated with SAP indicated that SAP also reduced the expression
of the M2-associated proteins MARCO (Fig. 3 E), ST2 and FIZZ-
1 (Fig. 3 F); as well as attenuating the bleomycin-induced pro-
fibrotic mediators CCL2 (MCP1/JE) [14], and oncostatin M
(OSM) [15] (Fig. 3 E).
We also found a trend towards an increase in M1 macrophage-
associated NOS2 expression following SAP treatment (Fig. 3 E).
Moreover, SAP treatment increased the level of the M1
macrophage-associated chemokine IP10/CXCL10, in the circu-
lation of mice treated with SAP, in comparison to control treated
bleomycin-challenged animals (Fig. 3 G).
Due to the profound effect on alveolar macrophages, we next
compared the ability of locally delivered SAP to reduce bleomycin-
induced collagen deposition with intranasal SAP dosing, to
systemically delivered SAP. Here systemically or intranasally
dosed recombinant human SAP (rhSAP) significantly reduced
bleomycin-induced collagen generation and deposition when the
protein was dosed every other day from day 11 (Fig. 4 A,B).
Interestingly, dosing mice systemically on days 11, 12 and 13 had
the most pronounced effect on attenuating bleomycin-induced
increases in collagen deposition which suggests that effects on
circulating or extrapulmonary monocytes may be at least partially
responsible for the ameliorative effects seen in these models.
Discussion
Alternatively activated macrophages have been described in the
lungs of IPF patients [1], however the correlation with disease
severity and their presence in the periphery has not. Here we
determined an elevated M2 background in these patients, both in
the lung and circulation. We then tested the hypothesis that the
pro-fibrotic activation of monocytes/macrophages seen in many
types of human pulmonary fibrosis is central to the progression of
disease pathology. A previous study has highlighted the potential
for the short pentraxin SAP to inhibit bleomycin induced lung
fibrosis, in part through an inhibition of monocyte to fibrocyte
differentiation in vitro [6] and accumulation in vivo [7]. We
extended these studies to assess a more global effect on lung
monocyte biology. Our results demonstrate that the modulation of
macrophage activation in established bleomycin-induced lung
fibrosis inhibited bleomycin-induced increases in collagen
deposition.
To determine the clinical significance of specific macrophage
subtypes during lung fibrosis we initially assessed the environment
of the fibrotic lung. During IPF/UIP, there is an M2 skewed
milieu, as indicated by elevated IL13, IL1RA and resistin; and
decreased M1 macrophage-associated fractalkine/CX3CL1 in
comparison to the non-fibrotic normal margins of lung tumour
resection tissue. The likely source of IL13 in the IPF/UIP lung is
the lymphocyte. However, we have attempted to stain for IL13 in
IPF lung sections and found this to be technically challenging.
Moreover, the role of T cells during lung fibrosis is controversial
[16] and further studies with potential advances in technology to
help delineate the cellular source of IL13 would add to our current
understanding.
Similar results with IL1RA were seen in the peripheral blood,
where we found increased IL1RA in IPF/UIP. As the non-fibrotic
tissue used in this study is the normal margins of lung tumor
resections, this tissue may have contained tumour-associated
macrophages which have been reported to be skewed to a M2
phenotype [17]. Therefore, our results indicate that the macro-
phage phenotype in the IPF/UIP lung is even more dramatically
skewed towards this alternatively activated phenotype.
We next detected elevated M2 macrophages in the circulation
of IPF/UIP patients and this was further increased in patients that
have progressive lung disease. Interestingly, we also found elevated
M2 associated proteins in the circulation, suggesting an overall
elevated M2 background in these patients. Monocytes are capable
of differentiating into a multitude of cell types including fibrocytes
and alternatively activated M2 macrophages [18]. Due to the
pronounced extent of remodeling in the lungs of IPF patients prior
to any therapeutic intervention, we assessed the ability of SAP to
attenuate established bleomycin-induced lung fibrosis buy initiat-
ing dosing at day 11. In this model at this time point, significant
collagen deposition has occurred [19]. The anti-fibrotic effect
mediated by SAP on fibrocytes has been demonstrated however,
Table 2. Progressive vs Stable IPF.
Comparison Progressive (n=7) Stable (n=6) Composite P Value per Category
Sex Female 1 (14.3%) 1 (16.7%) 1.0
Male 6 (85.7%) 5 (83.3%)
Smoking History Ever 3 (42.9%) 2 (33.3%) 1.0
Never 4 (57.1%) 4 (66.7%)
Race Nonwhite 3 (42.9%) 1 (16.7%) 0.56
White 4 (57.1%) 5 (83.3%)
Obese Nonobese 5 (71.4%) 5 (83.3%) 1.0
Obese 2 (28.6%) 1 (16.7%)
Age Years 61.7611.7 72.067.30 0.09
Coronary Disease Incidence 1 (14.3%) 0 (100%) 1.0
Kidney disease Incidence 0 (100%) 0 (100%) NS
IPF Diagnosis Basis Biopsy 5 (71.4%) 5 (83.3%) 1.0
FVC (% predicted) 54.7610.3 67.5613.5 0.08
DLCO (% predicted) 52.8619.4 58.7621.3 0.63
Continuous variables are expressed as mean 6 standard deviation.
doi:10.1371/journal.pone.0009683.t002
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We hypothesized that similar effects would be seen on another
subset of pro-fibrotic cells derived from circulating monocytes,
namely the M2 macrophage. Indeed, our data indicate broad
effects on monocyte cell fate that extend beyond fibrocyte
differentiation and increase the repertoire of diseases for which
this protein may be therapeutically significant.
Recent evidence has suggested that alveolar macrophages can
derive from both the circulating monocyte pool as well as an
intermediate lung macrophage [20]. We observed comparable
efficacy when SAP was dosed systemically or locally to the lung.
Interestingly, the mice that were only dosed with SAP on days 11,
12 and 13 had the most profound amelioration of fibrosis at day
21. Pharmacokinetic analysis of human SAP in mice indicated that
the circulating half-life after intraperitoneal administration for this
protein was approximately 8 hours (data not shown). This suggests
that the durability of response exceeds the circulating properties of
the protein and may be via a modulation of cell phenotype.
Further, studies using labeled SAP indicated that intranasally
delivered SAP persisted with the lung at least 96 hours after
dosing, whereas systemically delivered SAP localized to the liver
(data not shown). Taken together these data suggests that the
duration of beneficial effects mediated by SAP extends beyond its
systemic half-life, and that the site of action may be in the
circulation as well as in the lung. This therefore further
demonstrates the potential utility of SAP to treat human disease.
Analysis of the macrophage phenotype during in vivo models
indicated that SAP inhibits the M2 phenotype in the lungs of mice
with pulmonary fibrosis. Extensive marker analysis of whole lung
tissue indicated an attenuation of multiple M2 macrophage-
associated markers, including IL13Ra2, and the scavenging
receptor MARCO. SAP significantly reduced other key pro-
fibrotic mediators produced by M2 macrophages including, FIZZ-
1 (found in inflammatory zone 1), CCL2 [14], OSM [15] and ST2
[21]. We also detected enhanced resistin levels in the lungs of IPF/
UIP patients. The murine equivalent of resistin is FIZZ-1 (found in
inflammatory zone 1) and has been previously associated with
fibrotic regions of lung fibrosis models [22]. Taken together, M2
associated markers elevated in IPF/UIP, namely IL13, CCL2 and
resistin, were all reduced in vivo with SAP treatment.
SAP also promoted an increase in the M1-associated marker,
NOS2, as well as increasing the M1-associated chemokine
CXCL10/IP10. The CXCL10/IP10 finding is of particular interest
as this chemokine, as well as being associated with an M1
Figure 2. Enhanced M2 monocyte/macrophage phenotype in IPF/UIP. (A–D) Levels of macrophage-associated mediators measured in lung
tissue biopsies taken from IPF/UIP patients (filled bars) or from the normal margins of lung tumors following resection (open bars). M2 macrophage-
associated IL13 (A), IL1RA (B) and resistin (C); and M1-associated fractalkine/CX3CL1 (D) from non-fibrotic (n=11) or IPF/UIP (n=13) lung tissue were
assessed using Luminex technology. *P#0.05 significance using Mann Whitney analysis.
doi:10.1371/journal.pone.0009683.g002
Figure 1. Increased M2 macrophage phenotype and markers in the circulation of IPF/UIP patients. (A–B) Plasma levels of IL1RA (A) and
MCP1/CCL2 (B) for controls (n=12), stable IPF/UIP (n=6) and progressive IPF/UIP (n=7) as described in Tables 1and 2 were determined using
Luminex
TM technology. (C) CD163 expression on CD14
+ monocytes isolated from IPF/UIP patients (filled bar, n=12) and healthy age-matched
controls (open bar, n=8) was assessed by flow cytometry. Mean 6 s.e.m. *P#0.01 **P#0.005 ***P#0.001 significance using Mann Whitney analysis
with Bonferroni correction.
doi:10.1371/journal.pone.0009683.g001
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PLoS ONE | www.plosone.org 5 March 2010 | Volume 5 | Issue 3 | e9683Figure 3. Attenuated bleomycin-induced lung fibrosis and M2 macrophage phenotype with SAP treatment. Mice challenged with
intratracheal bleomycin (0.05 U) on day 0 and dosed with SAP (6 mg/kg, i.p. filled bars) or control (PBS, i.p., open bars) on days 11–20 were evaluated
at day 21 for gross morphological changes visualized in H&E stained lung sections (A); collagen generation quantitated by hydroxyproline analysis (B);
procollagen IaI and procollagen III gene expression quantitated and normalized to b-actin by branched DNA technology (C). Macrophage phenotype
in the lung assessed following SAP treatment by immunolocalizing IL13Ra2 (D), gene transcript levels determined by branched DNA technology at
day 21 for NOS2, CCL2, oncostatin (OSM) and MARCO (E), and FIZZ1 and ST2 (F). (G) Plasma IP10/CXCL10 levels determined by Luminex technology.
Bars represent the mean 6 s.e.m. of a minimum of n=4 per group. Original magnification, 620. *P#0.05 significance using Student’s t-test.
doi:10.1371/journal.pone.0009683.g003
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PLoS ONE | www.plosone.org 6 March 2010 | Volume 5 | Issue 3 | e9683Figure 4. Local and abbreviated SAP treatment significant reduces bleomycin-induced collagen generation and deposition. Mice
were challenged with intratracheal bleomycin (0.03 U) on day 0 and dosed with SAP (6 mg/kg) every other day on days 11–19 intraperitoneally (i.p.,
filled bar) or intranasally (i.n., down-hatched bar); or dosed with SAP (10 mg/kg, i.p.) on days 11,12,13 only (cross-hatched bar); or dosed with control
(P5S, i.n., open bar) every other day on days 11–19. Collagen was quantitated biochemically (A) and visualized histologically (B). Original
magnification, 620. Bars represent the mean 6 s.e.m. of a minimum of n=5 per group. *P#0.05 significance using Mann Whitney t-test.
doi:10.1371/journal.pone.0009683.g004
M2 Macrophages in Fibrosis
PLoS ONE | www.plosone.org 7 March 2010 | Volume 5 | Issue 3 | e9683macrophage phenotype, also has other anti-fibrotic activities
including inhibiting fibroblast recruitment [23], recruiting IFNc-
producing NK cells [24] and reducing aberrant angiogenesis [25].
Overall this suggests an SAP-mediated inhibition of the M2
macrophage phenotype and that this may extend to the clinical
setting.
In addition to specific effects on fibrosis per se, modulation of
macrophage phenotypes could potentially decrease the rate and
severity of pulmonary infections and fatal exacerbations, which are
thought to occur in IPF/UIP patients due to an impairment in innate
immunity. Lastly, these findings could extend to other diseases
characterized by the M2 phenotype such as asthma and COPD.
Materials and Methods
Patients
All studies were performed with Human Investigations
Committee approval at Yale University School of Medicine or
University of Michigan School of Medicine. For the plasma and
monocyte studies, inclusion criteria were: All patients were greater
than 18 years of age who had been diagnosed with IPF/UIP based
on the ATS/ERS 2002 guidelines were eligible for enrollment.
Exclusion criteria included current or recent use (within 2 months)
of immunosuppression or experimental therapy; chronic infection
such as HIV, tuberculosis, or hepatitis; known pulmonary
hypertension, COPD, or asthma; unstable cardiovascular, renal
or neurologic disease; and inability to provide informed consent.
Healthy, age-matched controls who self-identified as normal were
recruited from the greater New Haven area. Following enrollment
and written informed consent, demographic data concerning age,
race, sex, and co-morbid conditions were collected on all subjects.
In addition, data regarding restrictive ventilatory defect (decreased
forced vital capacity, or FVC) and diffusion impairment (decreased
diffusion capacity for carbon monoxide, DLCO) and how the
diagnosis of IPF/UIP (biopsy or CT scan) was made were
obtained from chart abstraction on the patients with IPF/UIP.
After one year of follow up patient charts were reviewed for the
following IPF/UIP-relevant outcomes: Significant (10%) decline in
FVC in 6 months following enrollment, new oxygen requirement,
hospitalization or treatment for exacerbation of IPF/UIP, and
death by any cause. Patients who met one or more of these criteria
were considered ‘‘progressors’’ and those who did not were
considered ‘‘Stable’’ (Table 1).
Bleomycin-induced pulmonary fibrosis model
All in vivo bleomycin studies were conducted according to
University of Michigan’s IACUC regulations and protocols. To
induce pulmonary fibrosis, female C57Bl/6 mice were treated
with high dose (0.05 U/mouse) or standard dose (0.03 U) of
bleomycin (Blenoxane, Sigma, St. Louis, MO) intratracheally on
day 0, as previously described [25,26].
Human serum amyloid P
Human serum amyloid P (SAP) was purchased from EMD
biosciences as human serum derived SAP frozen in PBS without
sodium azide preservative. Recombinant human serum amyloid P
was produced by Promedior as PRM-151 from CHO-S cell
culture. PRM-151 was provided as a PBS preservative free
solution. SAP was dosed either intraperitoneally (i.p.) or
intranasally (i.n.) as stated in the Figure Legend.
Protein and mRNA analyses
For protein analysis, lung biopsy tissue from IPF/UIP patients
or from the normal margins of lung tumor resections, or lungs
from mice were homogenized in anti-protease buffer (Roche
Diagnostics Corp., Indianapolis, Indiana, USA) and processed as
previously described [26]. Protein levels were measured by bead
based Luminex
TM analysis or specific ELISA. For gene analysis,
total RNA was obtained using TRIzol reagent (Invitrogen)
according to the manufacturer’s instructions. In some instances,
mediator levels were normalized to protein content which was
determined using a standard Bradford protein assay. Gene
expression levels were quantitated using branched-DNA-technol-
ogy-based QuantiGene Reagent System (Panomics), according to
the manufacturer’s protocols. Transcript levels of fibrosis and
macrophage-related genes (procollagen I, procollagen III, NOS2,
CCL2, oncostatin M, MARCO, FIZZ1 and ST2) were normal-
ized to b-actin mRNA.
Collagen assessment
Collagen levels were determined in lung homogenates using an
established hydroxyproline assay as previously described [12].
Histologic analysis
Formalin-fixed and paraffin-embedded lung sections were
stained with hematoxylin and eosin to assess gross morphology
or Mallory’s trichrome stains to visualize collagen deposition.
Immunohistochemical localization of IL13Ra2i n
histological tissue sections
Formalin-fixed and paraffin-embedded lung sections were
analyzed for immunohistochemical localization of IL13Ra2a s
previously described [12]. Sections were blocked with normal rabbit
serum (Vectorstain ABC-AP kit, Vector Laboratories, Burlingame,
CA). Rabbit anti-mouse IL13Ra2a n t i b o d y( R & DS y s t e m s )a n d
control normal rabbit IgG were diluted in PBS to a final
concentration of 5 mg/ml. A secondary rabbit anti-goat biotinylated
antibody (Vector Laboratories) was added to each section, then each
slide was thoroughly washed and receptor localization was revealed
using HRP-Dab Staining Kit (R&D Systems).
In vitro monocyte isolation and flow cytometry
Thirty mLs of peripheral blood was drawn and processed as
previously described [11]. Briefly, following density gradient
separation with Ficoll-paque (Stem Cell Technologies) cells were
stained for flow cytometric analysis of CD14 (Miltenyi) and
CD163 (BD Pharmingen) expression. Flow cytometry and cell
sorting was performed using a BD FACSCalibur. Data were
analyzed using Flow Jo v 7.5 software (TreeStar, Inc).
Statistics
Normally distributed data are expressed as means 6 s.e.m. and
assessed for significance by Student’s t test or ANOVA as
appropriate. Data that were not normally distributed were assessed
for significance using the Wilcoxon rank sum test of Mann
Whitney U test where appropriate. Patient demographics were
compared using Student’s t-test or Mann Whitney analysis as
appropriate. Categorical variables were compared using Fisher’s
exact test. Multi-analyte comparisons were performed using
Mann-Whitney analysis. P values were determined for multiple
comparisons using the Bonferroni correction.
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